First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab (pmab) or bevacizumab (bev) in wild-type (WT) RAS metastatic colorectal carcinoma (mCRC): Tumor response outcomes beyond RECIST.
- Resource Type
- Journal
- Source
JOURNAL OF CLINICAL ONCOLOGY ; JAN 20 2015, 33 3, 1p. Supplement: S- Subject
- Language
- English
- ISSN
- 15277755